Rossari Biotech · NSE: ROSSARI · BSE: 543213
Q1 FY22 results · Apr–Jun 2021
Rossari Biotech reported revenue from operations of ₹231.11 crore (up 111.1% from Q1 FY21) and net profit of ₹24.54 crore (up 58.4% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 231.11 | 109.47 | +111.1% | 218.22 | +5.9% |
| Other income | 3.07 | 1.60 | +92.1% | 2.88 | +6.5% |
| Total income | 234.18 | 111.06 | +110.9% | 221.10 | +5.9% |
| Profit before tax | 33.24 | 20.38 | +63.1% | 29.91 | +11.1% |
| Net profit for the period | 24.54 | 15.49 | +58.4% | 22.20 | +10.5% |
| Attributable to shareholders of the company | 24.52 | — | — | 22.43 | +9.3% |
| EPS, basic (₹) | 4.52 | 3.19 | +41.7% | 4.32 | +4.6% |
| Net margin (%) | 10.6 | 14.2 | 10.2 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 203.95 | 109.47 | +86.3% | 201.48 | +1.2% |
| Other income | 3.27 | 1.58 | +107.3% | 2.54 | +28.9% |
| Total income | 207.22 | 111.05 | +86.6% | 204.02 | +1.6% |
| Profit before tax | 27.00 | 20.61 | +31.0% | 29.22 | −7.6% |
| Net profit for the period | 19.92 | 15.28 | +30.4% | 21.40 | −6.9% |
| EPS, basic (₹) | 3.67 | 3.14 | +16.9% | 4.12 | −10.9% |
| Net margin (%) | 9.8 | 14.0 | 10.6 |
Consolidated
- Filed with BSE
- 30 Jul 2021, 20:12 IST
- Board meeting
- 30 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jul 2021, 20:12 IST
- Board meeting
- 30 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Audited
- Source
- XBRL filing on BSE